ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP issued a shareholder-solicitation notice regarding a securities fraud class action against ADMA Biologics. The complaint alleges undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls between August 2024 and March 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.